Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

Table 2

Radiation-absorbed doses to organs from ¹⁸⁸Re-6D2 (mSv/MBq).

Cohort	Liver	Spleen	Kidneys	Bone marrow	Urine bladder wall	Whole body
Phase 1a
Cohort 1	0.88 ± 0.13	0.86 ± 0.09	1.35 ± 0.05	0.09 ± 0.01	0.88 ± 0.23	0.16 ± 0.01
Cohort 2	0.89 ± 0.20	0.67 ± 0.05	1.11 ± 0.22	0.11 ± 0.02	1.01 ± 0.12	0.15 ± 0.03
Cohort 3	0.90 ± 0.08	0.73 ± 0.14	1.59 ± 0.01	0.11 ± 0.0	0.86 ± 0.14	0.13 ± 0.02
Cohort 4	1.04 ± 0.30	0.67 ± 0.30	1.29 ± 0.12	0.14 ± 0.03	1.02 ± 0.08	0.16 ± 0.04
Phase 1b
Cohort 1	0.92 ± 0.20	0.93± 0.32	1.99 ± 0.17	0.11± 0.01	0.61 ± —*	0.14 ± 0.01
Cohort 2	0.77 ± 0.25	1.02 ± 0.35	1.75 ± 0.25	0.10 ± 0.01	0.95 ± 0.47	0.15 ± 0.03
Tositumomab	0.82	1.14	1.96	0.65	0.64	0.24
Ibritumomab tiuxetan	4.8	9.4	0.1	1.3	0.9	0.5

*Only one patient had sufficient data for calculation of urine bladder wall dose.